Reversal of neuroleptic-induced orofacial dyskinesia by 5-HT3 receptor antagonists

European Journal of Pharmacology

Volumn 420, Issue 2-3, 2001, Pages 113-117

  Naidu, Pattipati S ^a   Kulkarni, Shrinivas K ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

5 HT (5 hydroxytryptamine, serotonin); 5 HT3 receptor antagonist; Neuroleptic; Tardive dyskinesia; Vacuous chewing movement

Indexed keywords

HALOPERIDOL; ONDANSETRON; SEROTONIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; TROPISETRON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG INDUCED DISEASE; MALE; MASTICATION; NONHUMAN; OROFACIAL DYSKINESIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; TARDIVE DYSKINESIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; HALOPERIDOL; INDOLES; MALE; ONDANSETRON; RATS; RATS, WISTAR; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS;

EID: 0035946981     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(01)00986-4     Document Type: Article

References (33)

1. Neurotoxicity associated with neuroleptic induced oral dyskinesias in rats implications for tardive dyskinesia?
2. 3 receptor release dopamine from rat striatal slices
3. 3 receptor ligands
4. Tardive dyskinesia: Pathophysiology
5. Tardive dyskinesia: Pathophysiology and animal models
6. 3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain
7. Treatment of tardive dyskinesia
8. 2 receptor occupancy in clozapine treated patients
9. Neurobiological substrates of tardive dsykinesia: The GABA hypothesis
10. LSD, mescaline and serotonin injected in to medial raphe nucleus potentiates apomorphine hypermotility
11. The distribution of monoamine terminals in the central nervous system
12. Treatment of phenothiazine-induced dyskinesia
13. Oral dyskinesia in rats following brain lesions and neuroleptic drug administration
14. Tardive dyskinesia: Review of treatments past, present, and future
15. VII International union of pharmacolology classification of receptors for 5-hydroxytryptamine
16. Structure and function of the brain serotonin system
17. Serotonin-dopamine interaction and its relevance to schizophrenia
18. 3 receptors: A review of their pharmacological and therapeutic aspects
19. Understanding the mechanism of action of a typical antipsychotic drug: A review of components in use and developments
20. Modulation of oral movements by intranigral 5-hydroxytryptamine receptor agonists in the rat
21. Increased sensitivity to D- and L-amphetamine action after midbrain raphe lesions as measured by locomotor activity
22. Serotonergic involvement in haloperidol-induced catalepsy
23. Facilitation of a dendritic calcium conductance by 5-hydroxytryptamine in the substantia nigra
24. 3 mediated control of dopaminergic function
25. Rolipram, a selective c-AMP phosphodiesterase inhibitor supresses oro-facial dyskinetic movements in rats
26. Receptors selectivities of atypical neuroleptics
27. Serotonin function in tardive dyskinesia
28. Use of the selective serotinin 3 receptor antagonist ondansetron in the treatment of neuroleptic induced tardive dyskinesia
29. 2 receptors
30. The pathophysiological basis of tardive dsykinesia
31. 3 like receptors in the action of clozapine
32. 3 receptors in the cerebral cortex and superior cervical ganglion of the rat
33. 3 receptor antagonist